title: [Combined treatment in patients with carcinoma in situ of the urinary bladder using intravesical pirarubicin, irradiation and hyperthermia].
abstract: The treatment with hyperthermia in combination with radiation and intravesical pirarubicin (THP-ADM) was preliminary investigated in 5 patients with urinary bladder carcinoma in situ. Following intravesical administration of 30 mg THP-ADM, external irradiation of 3.0 Gy was delivered to the urinary bladder. Immediately then, hyperthermia using Thermotron RF-8 was performed for 50 min (intravesical temperature: 42-43 degrees C for 35 min). After five courses of the treatment, complete response has been maintained for 6, 8, and 9 months in 3 patients. However, in a patient with complete response, urinary cytology became positive in the 6th month after the treatment. In the remaining patient treatment was interrupted after only 3 courses due to urinary irritation, urinary cytology didn't become negative. The side effects of the combined treatment were limited to the transient symptoms of bladder irritation in all patients and thermal burn in 2 patients. These preliminary results suggest that this combined treatment may represent an effective conservative therapy for patients with urinary bladder carcinoma in situ.
authors.affiliation: Department of Radiology, National Hospital Shikoku Cancer Center.
authors.forename: T
authors.initials: T
authors.lastname: Takechi
authors.forename: M
authors.initials: M
authors.lastname: Kawamura
authors.forename: H
authors.initials: H
authors.lastname: Nakagawa
authors.forename: S
authors.initials: S
authors.lastname: Inatsuki
authors.forename: K
authors.initials: K
authors.lastname: Akiyama
authors.forename: M
authors.initials: M
authors.lastname: Yano
authors.forename: Y
authors.initials: Y
authors.lastname: Sumiyoshi
authors.forename: K
authors.initials: K
authors.lastname: Mandai
authors.forename: S
authors.initials: S
authors.lastname: Moriwaki
authors.forename: M
authors.initials: M
authors.lastname: Kataoka
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000628:therapy*
chemical_list: D004317:Doxorubicin; C027260:pirarubicin